EDP 317

Drug Profile

EDP 317

Alternative Names: ACTB-1003; EDP317; MMKI - ACT Biotech; Multi-mode kinase inhibitor - ACT Biotech

Latest Information Update: 21 Oct 2015

Price : $50

At a glance

  • Originator Bayer HealthCare
  • Developer ACT Biotech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Fibroblast growth factor receptor antagonists; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 21 Oct 2015 Eddingpharm plans a phase I trial for Cancer in USA
  • 08 Jan 2014 Phase-I clinical trials in Cancer in USA (PO)
  • 08 Jan 2014 ACTB 1003 licensed to Eddingpharm worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top